The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Sarcopenia and altered body composition following abiraterone acetate (AA) and corticosteroid (C) treatment in men with castration-refractory prostate cancer (CRPC).
Deborah Mukherji
Employment or Leadership Position - Institute of Cancer Research (U)
Honoraria - Janssen Pharmaceutical
Other Remuneration - Sanofi
Carmel Jo Pezaro
Employment or Leadership Position - Institute of Cancer Research (U)
Diletta Bianchini
Employment or Leadership Position - Institute of Cancer Research (U)
Nina Tunariu
Employment or Leadership Position - Institute of Cancer Research (U)
Amy Mulick Cassidy
Employment or Leadership Position - Institute of Cancer Research (U)
Aurelius Gabriel Omlin
Employment or Leadership Position - Institute of Cancer Research (U)
Shahneen Kaur Sandhu
Employment or Leadership Position - Institute of Cancer Research (U)
Gerhardt Attard
Employment or Leadership Position - Institute of Cancer Research
Consultant or Advisory Role - Janssen-Cilag
Honoraria - Janssen-Cilag
Johann Sebastian De Bono
Employment or Leadership Position - Institute of Cancer Research (U)
Consultant or Advisory Role - Johnson & Johnson
Honoraria - Johnson & Johnson